Rimantadine

From Proteopedia

proteopedia linkproteopedia link

spinqualitylabelsall models Rimantadine, also known as Flumadine Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

Better Known as: Flumadine

• Marketed By: Forest Labs
  
• Major Indication: Influenza Infection
  
• Drug Class: M2 Proton Channel Inhibitor
• Date of FDA Approval (Patent Expiration): 1993 (2001)
  
• 1994 Sales: N/A
• Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
• The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Pharmacokinetics

M2 Proton Channel Inhibitor Pharmacokinetics[1][2]
Parameter	Rimantadine	Amantadine
Tmax (hr)	4.3	2.5
Cmax (ng/ml)	310	402
Bioavailability (%)	>90	>90
Protein Binding (%)	40	67
T1/2 (hr)	27.7	~15
AUC (ng/ml/hr)	11917	5420
Dosage (mg)	100	100
Metabolism	Negligible	Negligible

References

1. ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473
2. ↑ Wang P, Liang YZ, Chen BM, Zhou N, Yi LZ, Yu Y, Yi ZB. Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. J Pharm Biomed Anal. 2007 Mar 12;43(4):1519-25. Epub 2006 Dec 6. PMID:17156962 doi:10.1016/j.jpba.2006.10.044